NOTE 7 – INTANGIBLE ASSETS, NET (Tables)

3 Months Ended

Mar. 31, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of March 31, 2020 and December 31, 2019:

The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of March 31, 2020 and December 31, 2019:

	March 31, 2020
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted-Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
Approved hormone therapy drug candidate patents	$	3,763,022	$	(542,235	)	$	3,220,787		12.75
Hormone therapy drug candidate patents (pending)		2,070,397		—			2,070,397		n/a
Non-amortizable intangible assets:
Multiple trademarks		325,648		—			325,648		indefinite
TOTAL	$	6,159,067	$	(542,235	)	$	5,616,832

	December 31, 2019
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted-Average Remaining Amortization Period (yrs.)
Amortizable intangible assets:
Approved hormone therapy drug candidate patents	$	3,463,082	$	(478,983	)	$	2,984,099		13
Hormone therapy drug candidate patents (pending)		1,979,299		—			1,979,299		n/a
Non-amortizable intangible assets:
Multiple trademarks		294,813		—			294,813		indefinite
TOTAL	$	5,737,194	$	(478,983	)	$	5,258,211

Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:

Estimated amortization expense, based on current patent cost being amortized, for the next five years is as follows:

Year Ending December 31,		Estimated Amortization
	2020 (9 months)	$	189,464
	2021	$	252,618
	2022	$	252,618
	2023	$	252,618
	2024	$	252,618